Premium
Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective
Author(s) -
Ebrahimi Safieh,
Ghorbani Elnaz,
Shafiee Mojtaba,
Ryzhikov Mikhail,
Hassanian Seyed M,
Azadmanesh Kayhan
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27725
Subject(s) - oncolytic virus , virotherapy , medicine , breast cancer , cancer , disease , potency , oncology , cancer research , immunology , biology , biochemistry , in vitro
Breast cancer is the most common cause of cancer death in women and presents a serious therapeutic challenge worldwide. Traditional treatments are less successful at targeting cancer tumors, leading to recurrent treatment‐resistant secondary malignancies. Oncolytic virotherapy (OV) is a novel anticancer strategy with therapeutic implications at targeting cancer cells by using mechanisms that differ from conventional therapies. Administration of OVs either alone or in combination with standard therapies provide new insights regarding the effectiveness and improvement of treatment responses for breast cancer patients. This review summarizes cellular, animal and clinical studies investigating therapeutic potency of oncolytic virotherapy in breast cancer treatment for a better understanding and hence a better management of this disease.